Hogan Lovells advises Vivalis in relation to its cross-border merger with Intercell
19 December 2012
Hogan Lovells has advised Vivalis, a French biopharmaceutical company, in relation to its cross-border merger with the Austrian vaccine-biotechnology company Intercell. A EUR 40 million capital increase is to be launched shortly after completion of the merger. The Fonds Stratégique d'Investissement (FSI) supports the merger and will participate in the capital increase.
Vivalis and Intercell merge to create the newly-named Valneva, a leading European biotechnology company specialised in vaccines and antibodies. Its headquarters will be located in Lyon and it shares listed on the regulated markets of NYSE Euronext Paris and the Vienna Stock Exchange.
Jean-Marc Franceschi, Equity Capital Markets corporate partner, and Arnaud Deparday, associate, advised on this transaction.
- ENDS –
About Hogan Lovells
For more information, see www.hoganlovells.com
Hogan Lovells is a leading global law firm providing business-oriented legal advice and high-quality service across its exceptional breadth of practices to clients around the world.
"Hogan Lovells" or the "firm" is an international legal practice that includes Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses.
The word "partner" is used to describe a partner or member of Hogan Lovells International LLP, Hogan Lovells US LLP or any of their affiliated entities or any employee or consultant with equivalent standing. Certain individuals, who are designated as partners, but who are not members of Hogan Lovells International LLP, do not hold qualifications equivalent to members.
For more information about Hogan Lovells, the partners and their qualifications, see www.hoganlovells.com.
Where case studies are included, results achieved do not guarantee similar outcomes for other clients.